Terms: = Breast cancer AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027
24 results:
1. Genomics and tumor microenvironment of breast mucoepidermoid carcinoma based on whole-exome and RNA sequencing.
Ge Y; Lin X; He J; Chen W; Lin D; Zheng Y; Yang L; Xu F; Li Z
Diagn Pathol; 2024 Jan; 19(1):15. PubMed ID: 38243319
[TBL] [Abstract] [Full Text] [Related]
2. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a torc1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
Davis SL; Ionkina AA; Bagby SM; Orth JD; Gittleman B; Marcus JM; Lam ET; Corr BR; O'Bryant CL; Glode AE; Tan AC; Kim J; Tentler JJ; Capasso A; Lopez KL; Gustafson DL; Messersmith WA; Leong S; Eckhardt SG; Pitts TM; Diamond JR
Clin Cancer Res; 2020 Sep; 26(17):4633-4642. PubMed ID: 32414750
[TBL] [Abstract] [Full Text] [Related]
3. Hyperactivation of torc1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant cancers.
Sudhan DR; Guerrero-Zotano A; Won H; González Ericsson P; Servetto A; Huerta-Rosario M; Ye D; Lee KM; Formisano L; Guo Y; Liu Q; Kinch LN; Red Brewer M; Dugger T; Koch J; Wick MJ; Cutler RE; Lalani AS; Bryce R; Auerbach A; Hanker AB; Arteaga CL
Cancer Cell; 2020 Feb; 37(2):183-199.e5. PubMed ID: 31978326
[TBL] [Abstract] [Full Text] [Related]
4.
Drago JZ; Formisano L; Juric D; Niemierko A; Servetto A; Wander SA; Spring LM; Vidula N; Younger J; Peppercorn J; Yuen M; Malvarosa G; Sgroi D; Isakoff SJ; Moy B; Ellisen LW; Iafrate AJ; Arteaga CL; Bardia A
Clin Cancer Res; 2019 Nov; 25(21):6443-6451. PubMed ID: 31371343
[TBL] [Abstract] [Full Text] [Related]
5. Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression.
Wang R; Liu Y; Liu L; Chen M; Wang X; Yang J; Gong Y; Ding BS; Wei Y; Wei X
EBioMedicine; 2019 Feb; 40():118-134. PubMed ID: 30711520
[TBL] [Abstract] [Full Text] [Related]
6. crtc1-MAML2 fusion in mucoepidermoid carcinoma of the breast.
Bean GR; Krings G; Otis CN; Solomon DA; García JJ; van Zante A; Camelo-Piragua S; van Ziffle J; Chen YY
Histopathology; 2019 Feb; 74(3):463-473. PubMed ID: 30380176
[TBL] [Abstract] [Full Text] [Related]
7. Combined Blockade of Activating
Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
[TBL] [Abstract] [Full Text] [Related]
8. The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.
Skálová A; Stenman G; Simpson RHW; Hellquist H; Slouka D; Svoboda T; Bishop JA; Hunt JL; Nibu KI; Rinaldo A; Vander Poorten V; Devaney KO; Steiner P; Ferlito A
Am J Surg Pathol; 2018 Feb; 42(2):e11-e27. PubMed ID: 29076877
[TBL] [Abstract] [Full Text] [Related]
9. Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/torc1/ZEB1 pathways in colon cancer.
Kan JY; Yen MC; Wang JY; Wu DC; Chiu YJ; Ho YW; Kuo PL
Oncotarget; 2016 May; 7(21):31336-49. PubMed ID: 27150059
[TBL] [Abstract] [Full Text] [Related]
10. miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia.
Jiang X; Hu C; Arnovitz S; Bugno J; Yu M; Zuo Z; Chen P; Huang H; Ulrich B; Gurbuxani S; Weng H; Strong J; Wang Y; Li Y; Salat J; Li S; Elkahloun AG; Yang Y; Neilly MB; Larson RA; Le Beau MM; Herold T; Bohlander SK; Liu PP; Zhang J; Li Z; He C; Jin J; Hong S; Chen J
Nat Commun; 2016 Apr; 7():11452. PubMed ID: 27116251
[TBL] [Abstract] [Full Text] [Related]
11. Treatment of Triple-Negative breast cancer with torc1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent cancer Stem Cell Population.
Bhola NE; Jansen VM; Koch JP; Li H; Formisano L; Williams JA; Grandis JR; Arteaga CL
Cancer Res; 2016 Jan; 76(2):440-52. PubMed ID: 26676751
[TBL] [Abstract] [Full Text] [Related]
12. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Amin DN; Ruiz-Saenz A; Gulizia N; Moasser MM
Oncotarget; 2015 Dec; 6(38):41123-33. PubMed ID: 26516700
[TBL] [Abstract] [Full Text] [Related]
13. Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in breast cancer Cells Only When Grown in Nutrient-Poor Conditions.
Silvestri A; Palumbo F; Rasi I; Posca D; Pavlidou T; Paoluzi S; Castagnoli L; Cesareni G
PLoS One; 2015; 10(8):e0136250. PubMed ID: 26291325
[TBL] [Abstract] [Full Text] [Related]
14. mtorc1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
[TBL] [Abstract] [Full Text] [Related]
15. CREB-regulated transcription co-activator family stimulates promoter II-driven aromatase expression in preadipocytes.
Samarajeewa NU; Docanto MM; Simpson ER; Brown KA
Horm Cancer; 2013 Aug; 4(4):233-41. PubMed ID: 23584792
[TBL] [Abstract] [Full Text] [Related]
16. Investigational drug MLN0128, a novel torc1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Gökmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW
Breast Cancer Res Treat; 2012 Dec; 136(3):673-82. PubMed ID: 23085766
[TBL] [Abstract] [Full Text] [Related]
17. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract] [Full Text] [Related]
18. Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer.
Yang X; Turke AB; Qi J; Song Y; Rexer BN; Miller TW; Jänne PA; Arteaga CL; Cantley LC; Engelman JA; Asara JM
Cancer Res; 2011 Sep; 71(18):5965-75. PubMed ID: 21775521
[TBL] [Abstract] [Full Text] [Related]
19. PIKing the right patient.
Turke AB; Engelman JA
Clin Cancer Res; 2010 Jul; 16(14):3523-5. PubMed ID: 20538763
[TBL] [Abstract] [Full Text] [Related]
20. Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis.
Horak P; Crawford AR; Vadysirisack DD; Nash ZM; DeYoung MP; Sgroi D; Ellisen LW
Proc Natl Acad Sci U S A; 2010 Mar; 107(10):4675-80. PubMed ID: 20176937
[TBL] [Abstract] [Full Text] [Related]
[Next]
